Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$3.24
+1.4%
$3.35
$2.71
$4.73
$620.55M1.2961,096 shs354,262 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.03
+13.1%
$0.03
$0.02
$0.15
$2.22M1.8994,738 shs2,164 shs
Kamada Ltd. stock logo
KMDA
Kamada
$7.76
+0.2%
$7.03
$5.08
$9.16
$453.14M0.9696,352 shs23,331 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.00%+3.35%-4.85%+0.15%+2.37%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00%+3.16%+24.05%+17.60%-78.71%
Kamada Ltd. stock logo
KMDA
Kamada
0.00%+0.60%+14.40%+29.48%+50.60%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
1.47 of 5 stars
3.50.00.00.00.02.50.6
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.2773 of 5 stars
0.03.00.00.00.61.70.0
Kamada Ltd. stock logo
KMDA
Kamada
3.9245 of 5 stars
3.33.00.00.02.51.73.1
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5070.02% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00
N/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
2.67
Moderate Buy$13.0067.61% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ABUS, GRTX, KMDA, and NBRV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$6.40M96.77N/AN/A$0.51 per share6.34
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Kamada Ltd. stock logo
KMDA
Kamada
$160.95M2.77$0.48 per share16.03$4.51 per share1.72
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$0.35N/AN/AN/AN/A-99.34%8/12/2025 (Estimated)
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2926.7424.240.969.60%6.31%4.43%8/13/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A

Latest ABUS, GRTX, KMDA, and NBRV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.04
6.01
6.01
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
9.74
9.74
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
20.30%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
12.90%
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
1.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
90191.53 million152.65 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3075.46 million47.38 millionOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable

Recent News About These Companies

Nabriva Therapeutics plc (NBRVF)
Meitheal gains rights to Contempo
Meitheal gains rights to CONTEPO from Nabriva in North America
Nabriva Therapeutics PLC NBRVF
Nabriva Therapeutics files patent for a dosing regimen for fosfomycin treatment
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis
Nabriva's stock is up after sharing antibiotic news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.24 +0.05 (+1.41%)
Closing price 07/3/2025 03:14 PM Eastern
Extended Trading
$3.24 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Galera Therapeutics stock logo

Galera Therapeutics NASDAQ:GRTX

$0.03 +0.00 (+13.08%)
As of 07/3/2025 11:58 AM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Kamada stock logo

Kamada NASDAQ:KMDA

$7.76 +0.02 (+0.21%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$7.78 +0.03 (+0.36%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.